| Identification | Back Directory | [Name]
2H-1-Benzopyran-2-one, 7-methoxy-6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propoxy]-3,4-dimethyl-, hydrochloride (1:1) | [CAS]
209969-60-8 | [Synonyms]
KA672
KA 672
KA-672 HCl
Ensaculin HCl
Anseculin Hydrochloride
2H-1-Benzopyran-2-one, 7-methoxy-6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propoxy]-3,4-dimethyl-, hydrochloride (1:1) | [Molecular Formula]
C26H33ClN2O5 | [MDL Number]
MFCD00933781 | [MOL File]
209969-60-8.mol | [Molecular Weight]
489.01 |
| Hazard Information | Back Directory | [Description]
Ensaculin, also known as KA-672, is a NMDA antagonist and a 5HT1A agonist potentially for the treatment of Alzheimer's disease (AD). Ensaculin showed memory-enhancing effects in paradigms of passive and conditioned avoidance in both normal and artificially amnesic rodents. It exhibited neuroprotective activities in an NMDA toxicity model and neurotrophic effects in primary cultured rat brain cells. In receptor-binding studies, ensaculin was found to have high affinities to serotonergic 5-HT(1A) and 5-HT(7) receptors, adrenergic alpha(1), and dopaminergic D(2) and D(3) receptors. | [Uses]
Ensaculin is an NMDA receptor channel blocker. Ensaculin has neuroprotective effects in NMDA toxicity models and promotes neuronal growth in primary cultures of rat brain cells. Ensaculin has the potential to be developed as an anti-dementia drug that acts on various neurotransmitter systems[1]. | [References]
[1] Hoerr R, et al. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. DOI:10.1111/j.1527-3458.2002.tb00220.x |
|
|